Tags Posts tagged with "Trump"

Trump

0 2287

The marijuana sector is one of the quickest growing industry’s in the country — projections for this year could add up to billions of dollars in sales. However with a new administration at the wheel in Washington, D.C., one that is potentially less favorable to legalization, marijuana entrepreneurs and investors alike are dealing with a difficult time.

Startups, analysts, and investors convened this week at the Marijuana Business Daily’s Conference and Expo just outside the nation’s capital in Oxon Hill, Maryland. The issue on everyone’s minds: what the marijuana industry is depicted as under a Trump presidency, as Attorney General Jeff Sessions and Press Secretary Sean Spicer have indicated the possibility for sterner enforcement at the federal level, where marijuana is technically illegal. The Department of Justice did not immediately respond to request for comment.

“I am concerned about what I am hearing, but we’ve been through several administrations at this point, and this is a matter of states’ rights,” stated Christie Lunsford, COO of Pro MAX Grow, which sells LED horticultural lighting for licensed marijuana growers and is based in Tappan, N.Y.

“I think the impact we will see coming out of Washington, D.C., is fewer investors coming into space … fewer people launching businesses direct to the plant — cultivation, dispensing and manufacturing. That’s where you’re going to see people not wanting to enter the cannabis space,” she stated.

To date, the growth of the industry is undeniable, with marijuana legalized for recreational use in eight states and Washington, D.C., and for medicinal use in 30 states and Washington, D.C., per Marijuana Business Daily.

Projections differ among industry critics, yet the numbers are large. Marijuana Business Daily makes a prediction that retail sales will hit $6.1 billion for 2017 and the industry could have a maximum economic impact of close to $68.4 billion by 2021; GreenWave Advisors set there prediction at $7.7 billion for 2017 and $30 billion by 2021 if recreational and medicinal cannabis is legalized through the entire country

1 3480

Cannabis shops and manufacturers have increasing concerns that the Trump Administration will enforce federal laws that restrict farming and selling the drug. This will reverse the president’s stance during his campaign and potentially overturn what has become a $7 billion industry. The worry was provoked by comments from White House spokesman Sean Spicer recently that the government would most likely boost its enforcement of drug laws.

Attorney General Jeff Sessions stated that he is “dubious” about the benefits of marijuana. He said, “Marijuana is against federal law, and that applies in states where they may have repealed their own anti-marijuana laws. So yes, we will enforce law in an appropriate way nationwide. It’s not possible for the federal government, of course, to take over everything the local police used to do in a state that’s legalized it. And I’m not in favor of legalization of marijuana. I think it’s a more dangerous drug than a lot of people realize.”

The comments have sparked worry with Chuck Smith, co-founder of Dixie Brands, a Denver-based company that manufactures topicals and edibles infused with THC, the active ingredient in cannabis. He founded the company in 2010 and now employs more than 100 people across Arizona, Colorado, California, and Nevada. Smith stated, “My concern right now for both the company and industry is just uncertainty. It’s hard to build an industry or a company when you don’t have clarity.”

The administration’s statements affected shares of Innovative Industrial Properties, which invests in cannabis-growing facilities and is one of the few publicly traded cannabis companies. Its stock price plummeted on the day of Spicer’s press conference and are down more than 13% since then. However, two other marijuana stocks, GW Pharmaceuticals and Cara Therapeutics, seem to have not been affected by the news.

Eight states now allow the use of cannabis recreationally, while more than two dozen states have legalized it for medical purposes. Twenty-one states have decriminalized cannabis. A recent Quinnipiac Poll found 71% of voters think the government should not restrict federal drug laws in states where marijuana is legal. Increasing acceptance has led to an jump in the market for cannabis in North America, with sales rising 34% to nearly $7 billion in 2016, according to Arcview Market Research. By 2021, the industry is likely to climb close to $22 billion.

Companies like Dixie Brands are charging that hike. The privately held company would not disclose current numbers, but in 2014 it was valued at $40 million. Smith said, “It’s hard for us to kind of go backwards. President Trump said he was going to allow this to be a state’s rights issue. We took him at his word.” Trump has sent mixed messages on cannabis. In the 1990s, he called for legalizing all drugs. On the campaign trail, he reiterated his support for medical cannabis and his deference to states to pass their own laws regulating the drug.

0 2712

On Thursday, Press Secretary Sean Spicer said the President understands the value of medical cannabis for those in need, however, recreational cannabis or adult-use is an issue for the Department of Justice to provide further clarification.

Spicer seemed to link marijuana use to the opioid addiction crisis plaguing the United States. Despite his un-educated attempt to link cannabis use to opioid addiction, a Johns Hopkins report published in August 2014 determined that states with legal marijuana programs have fewer prescription overdose deaths.

In January 2017, the National Academies of Sciences, Engineering and Medicine also released a review of 10,000 medical cannabis studies published since 1999. These data associated with these studies provide substantial evidence that supports the use of cannabis or its extracts for the treatment of chronic pain.

In November 2015, Forbes Magazine reported about a 60-Minutes episode that blamed the opioid crisis entirely on big pharmaceutical companies.

Cannabis advocates need to continue make their voices heard by respective state and local officials and legislatures to push back on this.

Stocks Under Pressure

Over the last few months, we have de-risked our leverage to the United States cannabis industry while increasing leverage to Nasdaq-traded biotech companies and Canadian cannabis companies.

We continue to remain favorable on the United States cannabis industry but expect to see weakness in the near-term and continue to focus on Canadian traded cannabis stocks as well as the biotech leaders.

Stocks we are watching and remain most favorable on include: GW Pharmaceuticals (GWPH), Emblem Corp (EMC.V) (EMMBF), Kush Bottles (KSHB), Canopy Growth (TWMJF) (WEED.TO), Zynerba Pharmaceuticals (ZYNE), Aphria (APHQF), Reliq Health (RQHTF) Aurora (ACBFF), VPR Brands (VPRB), Lexaria (LXRP), VinergyRes (VIN.CN), and Canabo Medical (CMM.V) (CAMDF).

mCig Announces 5 Million Reduction in Shares Outstanding

mCig Inc. ( OTCQB : MCIG ), a diversified company servicing the legal cannabis, hemp, and CBD markets, announced today that it has begun the process of cancelling 5 million shares of its common stock.

“We are announcing to our shareholders that we have reduced our shares of common stock outstanding by 5 million shares,” stated Michael Hawkins, CFO of MCIG. “Building value for shareholders in a public company requires not only success in establishing a strong business and revenue model, but also maintaining the financial integrity that comes from prudently managing the stock capital structure of the company. During our review we were able to identify and negotiate terms of service that led to the cancellation of prior stock issuances.”


Click Here To View Full Article


 

$VPRB will be participating at TPE Tobacco Plus Expo in Las Vegas

VPR Brands, LP (OTC PINK: VPRB) is proud to announce its participation in the TPE Tobacco Plus Expo booth# 6053, in Las Vegas, Nevada on January 25-26th. Voters in Nevada just recently voted to legalize marijuana for recreational use and the TPE show is the 1st major industry trade show to take place there since.

Dan Hoff COO of VPR Brands says, “The Trade Shows and events are a fantastic way for us to gauge the response to our new 2017 product portfolio. Having personally attended the BIG Industry Show in Los Angeles just last week, I had the opportunity to speak with many customers, industry professionals, and even some of our shareholders about the industry and their thoughts. The overall response to our products was overwhelmingly positive and with Nevada passing for recreational cannabis use in this past election I Believe the Tobacco Plus expo Las Vegas will have a large turnout from the Cannabis sector. According to Arcview Market Research’s official market projection annual legal cannabis sales in Nevada are expected to increase from $121.6 million in 2016 to an estimated $630 million by 2020.″


Click Here To View Full Article


 

#ICYMI: Marijuana Stocks, Inauguration Day, & Trump’s Bump

Here we are, just after the official inauguration day of our 45th President of the United States of America, Donald Trump. A lot has been said about him over the last few years during the election race but what many may not have expected was a clear “Trump Bump” for marijuana stocks.

 


Click Here To View Full Article


 

Pursuant to an agreement between MAPH and VPRBrands, we were hired for a period of 30 days to publicly disseminate information about (VPRB) including on the Website and other media including Facebook and Twitter. We are being paid $15,000 (CASH) for or were paid “ZERO” shares of unrestricted or restricted common shares. We own zero shares of (VPRB) which we purchased in the open market. . MAPH owns 2 million common restricted shares of mCig Inc. MAPH owns 10 million common restricted shares of Hemp Inc. We may buy or sell additional shares of any stocks mentioned, in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. PLEASE READ OUR FULL PRIVACY POLICY & TERMS OF USE & DISCLAIMER

0 2043

One of the decisions President Donald Trump will have to make is whether to move forward with the federal government’s hands off policy on cannabis, which has allowed the sale of the substance in 27 states. President Trump’s nominee for attorney general, Senator Jeff Sessions, has signaled that the new administration could end the practice of allowing states to legalize marijuana. Sessions stated, “It’s not so much the attorney general’s job to decide what laws to enforce. We should do our job and enforce laws as effectively as we’re able.”

Paul Callan and Danny Cevallos, from CNN, were asked for their views on the subject.

1. Cannabis is illegal under federal law. It’s a Schedule 1 controlled substance. Does the President have an obligation to enforce the law as written until the law is repealed?

Danny Cevallos: Yes. As a criminal defense attorney you might think I’d be anti-enforcement instead of pro-enforcement. But there’s no question that the President and the Attorney General are charged with enforcing the law. Arbitrary or selective enforcement of existing law is itself an abuse of power. The Equal Protection Clause already prohibits the “selective enforcement” of a law based on standards like race or religion. The broad discretion of the executive branch or a prosecutor to charge identical defendants with different crimes creates a real threat of unequal, and unconstitutional, treatment. If you want to legalize marijuana, the solution for the federal government is not to be willfully blind to existing federal law. That sends a bad message. The solution is to be proactive: get rid of the outdated federal law.

Paul Callan: No. Sure, Danny is correct that the President and the Attorney General are supposed to enforce the laws as written, but there is also an important concept called prosecutorial discretion. The government has limited resources and can choose to focus on terrorists, kidnappers, murderers and big-time white collar criminals rather than pot smokers listening to Daft Punk’s latest rendition of “Human After All.” The statute books are filled with laws that are not being enforced because they are obsolete and legislators haven’t gotten around to repealing them. There are an abundance of such laws listed in numerous internet sites. But more serious examples are closer at hand. For example, in 2013 the Justice Department issued a memo from Deputy Attorney General James Cole outlining a limited enforcement policy of only prosecuting federal marijuana criminal violations in cases of violence, interstate smuggling, distribution to minors and in matters of adverse impact on public health. Attorney General nominee Sessions would be wise to follow the Obama approach here, and President Trump should understand that there are a lot of electoral votes in those weed-legal states. And as for my friend Danny Cevallos; it is time for him to face reality and, as they say in Colorado, “chill.”

2. President Obama has excused thousands of drug offenders serving substantial amounts of time in prison for the sale and possession marijuana. Should President Trump continue with the Obama pardon policy given the number of states which have now legalized the drug?

Callan: Yes. President Trump would be wise to follow the example of his predecessor by making use of the pardon and commutation power, with care and discretion. The prisons are filled with inmates who have been sentenced to lengthy prison sentences for drug-related crimes. Many have gotten old in prison and no longer pose a threat to society. Many were unjustly convicted. We have seen a massive increase in costly, wrongful conviction lawsuits throughout the nation. Members of America’s minority communities have been aggrieved by what they perceive as the mass incarceration of their young men due to unjust drug laws that are no longer relevant in modern America. The pardons and commutations should be carefully monitored to make sure violent criminals are not slipping through the cracks but President Trump should follow President Obama’s example in continuing this policy.

Cevallos: No. Does anyone else think it’s a huge waste of resources for President Obama to pardon federal drug offenders instead of getting rid of the federal law that made many of them federal drug offenders in the first place? Think of the resources frittered away: existing federal law is what causes investigations, arrests, trials, appeals, and incarceration. Then, ultimately the same branch of government that spent all that time and money convicting the person grants a pardon or commutation, effectively canceling out all those resources spent getting the conviction. Wouldn’t it be a lot less expensive to get rid of the federal law that led to the expensive investigation, arrest, trial, appeal, and incarceration in the first place? President Obama’s pardon policy for drug offenders is a good thing, but it’s largely cosmetic, and it only conceals the bruises that the federal government itself continues to inflict upon the citizenry. Paul Callan wants to paint himself as a freedom fighter here, and he’s right that the pardon power is good for freeing those for acts no longer considered crimes. But true freedom isn’t pardoning the crime after the person has been incarcerated. It’s getting rid of the crime itself.

3. Republicans have commonly supported the doctrine of federalism. Should President Trump’s Republican Administration allow the states to experiment with cannabis legalization under the doctrine of federalism?

Cevallos: No. As Supreme Court Justice Louis Brandeis put it: “it is one of the happy incidents of the federal system that a single courageous State may, if its citizens choose, serve as a laboratory; and try novel social and economic experiments without risk to the rest of the country.” I agree completely with that general sentiment. But marijuana is different. States legalizing pot is “experimenting” with something that is flat-out illegal under federal law. When the threat of federal prosecution hangs over a marijuana shop owner or user, states cannot truly serve as laboratories. It’s hard to experiment when banks, investors, insurance companies, and even attorneys are reluctant to provide necessary services, for fear of federal criminal penalties or professional discipline. Paul Callan may cheer states for their open flouting of federal law, but would he represent a shop owner if he thought the bar association’s disciplinary committee would come after him? Heck no. He’s as afraid of the ethics board as I am. And so are plenty of other lawyers, who fear potential disciplinary action for counseling a client to engage in the business of violating federal law. Everyone loves the idea of civil disobedience, until it’s their turn to actually get hit with the fire hose or the police truncheon.

Callan: Yes. There is a lot of truth in a statement often heard in conservative gatherings: “The states created the federal government and not the other way around.” The Constitution was drafted by founding fathers deeply sensitive to the concept of a limited federal government with a vibrant democracy flourishing at the local level. Nowhere is the leadership of the states more clearly demonstrated than in the approval of recreational and medical marijuana in 27 states at last count. This state laboratory creates a superb opportunity to test different approaches to legalization rather than rely on the alleged wisdom of Cevallos’ elite pals in DC, many of whom have just been unceremoniously kicked out of office in the tumultuous election of 2016. Local authorities will ensure that rather than a “one size fits all” federal approach, the best state ideas will be imitated and implemented by other states. And as for the Cevallos claim that lawyers will never represent weed store owners for fear of an ethics prosecution, the Colorado Supreme Court has just given the weed lawyers the green light to represent marijuana businesses. Perhaps Danny Cevallos should consider opening a Denver office.

4. Should cannabis be legalized because taxing it will lead to a rich source of government revenue?

Cevallos: No. Don’t get me wrong. I think ending federal marijuana prohibition is a good idea. I also hope that taxing the drug will be a good source of revenue for states and the federal government. Paul Callan knows that this is a popular argument. But when you think about it, taxing vices hasn’t always been the cure for all ills. Gambling has been legal and taxed for years in places like Atlantic City, where it is the town’s primary industry. Has anyone strolled down that town’s main drag lately? It’s hardly a monument to American prosperity. Speaking of gambling, how about the lottery? State-sponsored gambling is heavily taxed and supposedly goes to help senior citizens and schools. But, would Paul Callan honestly say that the net effect of the lottery on society has been a good one? Hopefully marijuana taxation will be different. Early reports are positive: marijuana generates a lot of tax revenue in the legalized states. But there’s good reason to remain skeptical.

Callan: Yes, Danny raises a legitimate point that taxing vices often fails to raise the large amounts of revenue promised. Things like the lottery seem to generate more money for state bureaucracies than for education. Although Atlantic City looks grim, the gambling vice tax is thriving in Las Vegas, Indian Reservations around the country and even in Bethlehem, PA in Danny’s home state. The lesson is that you must carefully pick the vice you seek to tax. Given the track record to date marijuana seems a winner on the tax revenue side. In Colorado and Oregon, recreational use has spawned a $7.1 billion tax-generating industry. And for vice comparison purposes, the taxing of alcohol has proven to be quite lucrative to the states. Alcohol taxes yielded over $9 billion in revenues in 2015 with projections of $10.18 billion by 2021. As a drug which is arguably far less dangerous, marijuana is likely to generate an even greater revenue stream. The states are finding it difficult to overlook such a revenue stream given the thriving underground economy where only illegal producers and dealers enjoy the profit. If Mr. Trump really does want to lower corporate and personal income taxes, legalized, taxed marijuana may be of assistance in achieving that goal.

5. Many argue that cannabis is no more dangerous than alcohol, yet it’s illegal under the laws of many states and the federal government. Is it fair to treat the substances differently under law?

Callan: No. Wisely, Cevallos will not even fight me on this one. Marijuana is far less dangerous than alcohol and there is a great hypocrisy in permitting legal sales of the older generation’s vice, alcohol, while locking up younger Americans who partake of the far less dangerous marijuana. Of course it must be conceded that the drug is not without serious risks, particularly for those with a propensity toward drug abuse. This is yet another reason to allow experimentation on a state level to see how legalization works out in the real world. As for the Cevallos argument that a teetotaling POTUS will resist legalization, there are more than a few reasons to suggest otherwise. He has previously indicated support for medical marijuana stating: “In terms of marijuana and legalization, I think that should be a state issue, state-by-state. Marijuana is such a big thing. I think medical should happen, right? Don’t we agree? I think so. And then I really believe we should leave it up to the states.” Washington Post, October 29, 2015 And let’s face it, most liberals and progressives would have to be under the influence of drugs to support him, so there may be new Trump supporters if legalization succeeds. Though, let’s hope the new president maintains his teetotaling ways as heaven help us all if POTUS starts smoking “Trump Weed” before preparing his next 3 a.m. tweet.

Cevallos: No. Paul Callan has me here. Prohibiting marijuana and allowing alcohol makes zero sense. But then again, nothing about vice crimes is “fair” or even “logical.” In fact, alcohol is much more dangerous than marijuana. Not only is it bad for your body, it’s a major contributor to accidents, and violence. But the real question is: could Mr. Callan convince Mr. President? Our new POTUS is a self-described teetotaler, a nondrinker and non-drug user. And he’s not the kind who stopped drinking because he used to have a problem, who hit a Bukowski-like bottom and turned his life around in AA. Trump is the kind who says he has never had a sip of alcohol in his life. Those people are intense. They usually like order and control. It’s easy to imagine Trump might be intolerant of vices like marijuana. Then again, he’s been socially liberal in many ways too. It’s hard to predict where his administration will come down on the marijuana industry.

0 2486

Marijuana Stocks, Inauguration Day, & Trump’s Bump

Here we are, just after the official inauguration day of our 45th President of the United States of America, Donald Trump. A lot has been said about him over the last few years during the election race but what many may not have expected was a clear “Trump Bump” for marijuana stocks.


Click Here To View Full Article


 

Facts Regarding Denver’s New Marijuana In Public Law

Denver has begun working on the country’s first law allowing use in public places like coffee shops and cannabis clubs. However, the details about what those marijuana clubs would look like are still unclear. Here are some answers to questions about the cannabis clubs headed to Denver.


Click Here To View Full Article


 

Veterans In Support Of Medical Marijuana



Indiana American Legion reached an agreement on Sunday that would support a medical cannabis study to treat injuries to military service members, such as traumatic brain injuries and PTSD. The veteran service organization said they are working to urge Indiana legislators to approve the private growth and research of medicinal cannabis and to reclassify marijuana as a drug with potential medical value.


Click Here To View Article


 

 

 PLEASE READ OUR FULL PRIVACY POLICY & TERMS OF USE & DISCLAIMER

1 12371

How Have Marijuana Stocks Performed Post Trump?

Here we are, the official inauguration day of our 45th President of the United States of America, Donald Trump. A lot has been said about him over the last few years during the election race but what many may not have expected was a clear “Trump Bump” for marijuana stocks.

As we’ve said in the past, a lot of marijuana stocks are event driven. Going all the way back to 2014 and during the years to follow, catalysts in the cannabis market can be tied to actual events in many cases. For this most recent jump in marijuana stock prices, we see that an election year and a not so conservative President may be the event to thank for this.

In this article we’ll briefly explore some of the most active and most bullish marijuana stocks in the market to give a clear example of “where we’ve been” and what we might be able to look forward to as to “where we’re going”.

OWC Pharmaceutical Research Corp. (OWCP) 3,512%

This company has been building steam since October and just recently went into overdrive to all time highs. Through its subsidiary, One World Cannabis, the Israeli-based company develops cannabinoid-based therapies that target different medical conditions. This was another cannabis biotech company that saw the impact of Trump coming into office instead of Clinton (who was very bearish on biotech).

In late October just before the elections, OWCP saw its first noticeable move from under $0.03 and initially ran to highs of $0.215. Following the consolidation period heading into the end of the year (as most marijuana stocks saw), January opened the door for this stock to run as high as $0.95

OWCP_Marijuana_Stocks

 

Rocky Mountain High Brands (RMHB)
271%

We’ve reported on this company and followed it for a few years. Even before when it was “Totally Hemp Crazy (THCZ)” this stock saw one of the biggest breakouts that we’ve every witnessed. It went from sub penny to highs of 0.32 within weeks. Now it appears that chart has demonstrated a similar Trump Bump that many of the other marijuana stocks have also seen.

In early October, volume began to build, RMHB ran from $0.031 to highs of $0.07. After consolidating back to 0.03-0.04, RMHB has now seen its 2017 rally trigger and has now managed to run past $0.11. Rocky Mountain is a consumer goods company specializing in brand development of health conscious, hemp-infused food and beverage products. The Company currently markets a lineup of four naturally flavored hemp-infused beverages (Citrus Energy, Black Tea, Mango Energy and Lemonade) and a low-calorie Coconut Lime Energy drink. Rocky Mountain High Brands also offers hemp-infused 2oz. Mango Energy Shots and Mixed Berry Energy Shots, as well as a Relaxation Brownie.

Marijuana Stock

Ubiquitech Software Corp. (UBQU)
304%

UBQU follows a similar trend where even though it hasn’t broken above its year end highs, the stock has seen a reversal that started at the beginning of 2017. A lot of questions were raised regarding a previously announced name change and recently the company gave clear guidance on this for 2017 that has brought attention back to the stock from market bulls. Its final name change will be Endo BioSciences Inc., and HempLife Today™ will continue to be the main subsidiary of the company.

HempLifeToday™ focuses on the exciting and dynamic new thinking in the world today that recognizes the important health and life enriching enhancement that CBD Oil from the Hemp plant can bring. Through its network of quality USA growers HempLifeToday.com™ has developed multiple and proprietary CannazALL™ CBD oil products that include; its popular CBD Tinctures, Oils, GelCaps, CBD Powder, Skin Salve, Wax Crumble, and e-liquid.

marijuana stocks

mCig, Inc. (MCIG)
1,265%

A company that we’ve kept up with for the better part of the last year, MCIG became another clear example of what marijuana stocks have started to look like after Donald Trump was elected President. The company has been making many key strides over the last few months including posting some of its best numbers in history.

This includes MCIG currently holding over $10 million in order/contract backlog (as of their last PR in December). In similar fashion to OWCP, shares of MCIG saw a bump in late October when the stock moved from under $0.04 to as high as $0.218. After consolidating in early December, MCIG manage to rally strong heading into the end of the year and recently hit highs of $0.505.

cannabis stocks

Axim Biotechnologies, Inc. (AXIM)
3,941%

Another company that we’ve been following very closely, this has been one of the biggest runners of the year amid heavy volatility. Another cannabis biotech, the company focuses on the research, development and production of cannabis-based pharmaceutical, nutraceutical and cosmetic products. Our flagship products include CanChew®, a CBD-based controlled release chewing gum, and MedChew Rx, a combination CBD/THC gum that is undergoing clinical trials for the treatment of pain and spasticity associated with multiple sclerosis. MJNA is also an investor in AXIM.

In late October the stock was trading just under $0.50 moved to a high of $10 before consolidating to levels between $7.50-$8. Wouldn’t you know it, heading into the beginning of 2017 the stock broke the sideways trend and moved to highs of $19.80.

cannabis stock

Vitality Biopharma (VBIO)
361%

A company that many of us are familiar with, this cannabis biotech had a smaller run a few weeks before we started picking up coverage. In early October, the stock moved up from around $0.92 to highs of $1.84. After pulling back to lows in December, we began looking at this company at $0.98 and watched as it ran to highs of $4.24. The company is a cannabis biotech focusing on treating disease through its prodrug utilizing cannabinoids for the treatment of serious neurological and inflammatory disorders.

marijuana

Cannabis Science (CBIS)
469%

The company specializes in the development of cannabinoid-based medications and recently announced a collaborative research agreement with Dana Farber/Harvard Cancer Center. Their initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.

From October 3 to October 19 CBIS jumped from $0.0169 to as high as $0.077. After pulling in during December, the stock kicked off the new year with a big bull run all the way to highs of $0.0961 for the year so far.

cannabis

Hemp Inc. (HEMP)
103%

One of the most vocal companies on Hemp production in the US, Hemp Inc. They’ve continued to push for a ubiquitous acceptance for all uses of the hemp plant for years now and have targeted North Carolina to grow over 3,000 acres of hemp.

“We are proud to collaborate with other American industrial hemp farmers as we now become part of the modern industrial hemp farming movement. This is a turning point for America and it’s a turning point for Hemp, Inc. Hemp, Inc. has the infrastructure in place to process millions of pounds of hemp fibers and stalks a year, on a commercial level. Our 70,000 square foot industrial hemp processing facility, on over 9 acres in Spring Hope, North Carolina, is the only one of this magnitude in North America. The industrial hemp crop is part of history in the making and it is something that will prove to be lucrative not only for the farmers in North Carolina but for Hemp, Inc. as well,” said CEO Bruce Perlowin in a recent PR.

HEMP saw a bump in volume early in October, the stock ran from $0.0276 to $0.056 before consolidating in late November/December, and has once again begun to aggressively climb back from that price channel.

hemp

Cannabis Sativa, Inc. (CBDS)
195%

With multiple subsidiaries, this company has products ranging from hemp oils & capsules to cannabidiol infused bottled water and even its own patented cannabis plan named Ecuadorian Sativa (Patent PP27,475). Back in late September the stock was trading around $2.80 per share before it jumped up to highs of $8.25. After consolidating for weeks leading up to the new year, CBDS has once again followed suit of many marijuana stocks having now climbed back above $8.

CBD

OH CANADA!

This leads us to our “neighbors up north” because we haven’t just seen a boom from US marijuana stocks alone. The trend has echoed into Canada with some of the most anticipated IPOs so far this year

Emblem Corp. (TSXVENTURE:EMC)(OTCQB:EMMBF)
55%

Emblem Corp, a Licensed Cultivator out of Paris Ontario is one of the most watched and anticipated offerings that has come out of Canada in the last few months. Beyond the fact that they are already growing cannabis and revenue producing investors have taken note of one of their founders and current President, a gentleman by the name of John Stewart.

No, not John Stewart from the Daily Show even though that would be awesome, John Stewart former CEO of Purdue Pharma one of the largest private biotech companies in the world and creators of OxyContin. We see the potential long term to create a cultivator/Biotech hybrid in which case Emblem could be the Next GW Pharma of Canada.

Marijuana IPO

InMed Pharmaceuticals, Inc. (OTCQB: IMLFF) (CNSX: IN)
326%

This company has been following the same pattern as many of the other cannabis biotechs but also comes with what looks to be a stock promotion behind it. The company recently appointed Jeff Charpentier, CPA, CA as InMed’s Chief Financial Officer & Corporate Secretary as well as Martin Bott to its Board of Directors; Bott has worked at Eli Lilly & Company since 1988 and held a variety of roles in the U.S., Switzerland, Germany, and the UK.

InMed is a pre-clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. IMLFF saw a rise in price early in October (shocker right?), a period of consolidation leading up to the new year, and since that ball dropped, the stock has been on the run moving from $0.10 in October to highs of $0.4261 just a few days ago.

Marijuana Stocks

Aurora Cannabis Inc. (TSXV: ACB) (OTCQB: ACBFF)
179%

The company’s wholly-owned subsidiary, Aurora Cannabis Enterprises Inc., is a licensed producer of medical cannabis pursuant to Health Canada’s Access to Cannabis for Medical Purposes Regulations (ACMPR) and operates a 55,200 square foot, expandable, state-of-the-art production facility in Mountain View County, Alberta, Canada.

They just announced that the company has officially surpassed 12,000 registered patients within the first 12 months of product sales in Canada. They also announced that they had signed a Joint Venture Research Agreement with Radient Technologies Inc. (“RTI”). The first phase of this venture will include screening experiments of extraction conditions, while phase two includes larger scale experiments related to extraction throughput and optimal extraction conditions. Aurora’s scientists and the RTI team will commence tests January 16, 2017, and the first phase is expected to be completed within approximately six weeks, so something to keep an eye on here in our opinion.

Likewise with the other stocks, the market activity has followed suit even though Aurora has differed by not breaking a new high this year as compared to the high it made in November. But the new uptrend on the chart could be a key indicator for future potential. Since October (at $1.06), shares of ACBFF has seen two and possibly three clear runs; One that saw highs of $1.89 before consolidating, another that saw highs of $2.96 before consolidating, and possibly a new uptrend forming now in January.

Buy marijuana stocks

These are just a few marijuana stocks that have demonstrated a near identical move in the market both leading into the election and leading up to the inauguration. We’ve said it before and most likely will say it again: Marijuana Stocks can very much be event driven so something to keep in the back of your head as we watch 2017 unfold. As investors become more informed on the industry itself, we’ll keep our had on the pulse to find the real story behind some of the biggest marijuana stock moves in the market today.

 

 

 

 

 


 

Pursuant to an agreement between MAPH and a non affiliate third party, we were hired for a period of 30 days to publicly disseminate information about (VBIO) including on the Website and other media including Facebook and Twitter. We are being paid $100,000 (CASH) for or were paid “ZERO” shares of unrestricted or restricted common shares. We own zero shares of (VBIO) which we purchased in the open market. We plan to sell “ZERO” shares of (VBIO) that we hold during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. Pursuant to an agreement between MAPH and Ubiquitech Software Corp., we were hired for a period beginning November 11 2016 and ending May 11, 2017 to publicly disseminate information about (UBQU) including on the Website and other media including Facebook and Twitter. We are being paid $0 (CASH) for or were paid “10 million” shares of restricted common shares. MAPH owns 2 million common restricted shares of mCig Inc. MAPH owns 10 million common restricted shares of Hemp Inc. An affiliate of MAPH owns 70,850 common restricted shares of Emblem Corp. We may buy or sell additional shares of any stocks mentioned, in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information

1 5719

Marijuana is being talked about a lot in these past few days. This is because nine states voted about legalizing either medical or recreational marijuana in this election. With these new amendments being passed, a lot is going to change for better or for worse with the medical marijuana industry.
However, what people are really wondering is how Trump and his presidency are going to affect the future of marijuana. According to Trump, he is “100% in favor of medical marijuana”. Trump proposed that he would reschedule marijuana from its current illegal status as a Schedule 1 substance to possibly a Schedule 2 or lower, if he won the election. Schedule 1 substances are considered federally illegal and supposed to have no medical benefits, whereas Schedule 2 substances and lower are considered to have medical benefits but also are perceived to have addictive qualities. Now that he has the power to affect change, the industry may see some changes.

Trump’s proposal will have a large effect on the marijuana industry as it would make marijuana a regulated drug. This means that the FDA will be able to strictly control the drug. This will impact the industry as it will allow the FDA to force the medical cannabis companies to prove via clinical trials the actual effect of medical marijuana on patients. These trials take time and a lot of money. So while in retrospect it seems like decriminalizing marijuana will make it more accessible to people in need, it will actually negatively impact people who desperately need it for medical issues.

In terms of recreational marijuana, Trump is less hands on. He has yet to suggest the federal government’s involvement in recreational marijuana and it appears as if for the time being, the decision will fall on state legislature. It cannot be determined exactly what Trump will do in his presidency and how the industry will be affected, but this election might prove bittersweet for the medical marijuana industry.

0 1572

One big issue this election has set it apart from all of the other elections in the past. One of the biggest issues of the 2016 election is marijuana legalization. The extraordinary number of cannabis measures on the ticket in November, incorporating into two swing states, could muddle turnout in the 2016 presidential race, bringing out more voters, yet not dependable for any applicant.

At first look, the customary demographic of pot voters – white, youthful, male, Democratic – would probably build votes in favor of Clinton. In any case, with the Libertarian applicant (and known pot lover), Gary Johnson, having the most obvious opportunity since Nader to siphon votes far from a standard hopeful, and the erratic dependability of partisan principal voters this year, it’s not ensured that Clinton will have the capacity to capitalize on the force of pot.

“Polls show that there’s a trend toward marijuana legalization, so the energy behind this issue seems to be on the legalization side,” Geoffrey Skelley, media relations coordinator for the University of Virginia’s Center For Politics, stated. “So if there are citizens who turn out and vote because of this issue, it’s probably going to favor Democrats.”

In any case, Skelley highlights, a specific cut of voters persuaded by weed legislative issues may not bolster Clinton or Trump.

“You’re talking about a group that’s more white male than not, and even at younger ages, they don’t view Clinton favorably. Romney won 18- to 29-year-old white men in 2012, and that’s a group Trump should hope to be winning. So he should be worried that Gary Johnson could steal some votes from him there. After all, young men who are white are a potentially good voting group for Johnson, so higher turnout related to marijuana legalization might hurt Trump, even at the margins.”

0 1230

$NEWC: Sannabis Makes Headlines After Products Showcased at the Inauguration of First Medical Marijuana Co-Op

New Colombia Resources, Inc. (NEWC), a Colombian company listed in the U.S., is pleased that Sannabis SAS, their Medical Marijuana joint venture, continues to make headlines. Sannabis products were showcased at an inaugural event for Caucannabis, Colombia’s first medical marijuana co-operative that includes 52 Indigenous families that will legally grow medical marijuana.

Caucannabis was formed by mayors of the Department of Cauca, home to Sannabis and Colombia’s largest marijuana growing region, where 50% of the nation’s marijuana is grown. The inauguration made major headlines due the visit from Colombia’s Ministers of Justice and Health who support this co-operative.

Sannabis has been growing medical marijuana and producing high quality, organic products in Cauca since 2014. In April they hosted the mayors of the Cauca Department at their facilities to be used as a model for the co-op. Sannabis is increasing their production to satisfy the demand for medical marijuana medicines, the addition of the co-op will add to the Sannabis supply chain.

 


Click Here To View Full Release



Trump’s VP Candidate Proves Bad News for Cannabis Reform

Donald Trump has just chosen Indiana Gov. Mike Pence as his vice presidential running mate, proving bad news for those who hoped for a cannabis policy reform during the next presidency. Indiana still holds draconian drug laws, where possession of any amount of cannabis is still punishable by a $1,000 fine and 180 days in jail. House Bill 1006 was introduced in 2013 as an effort to overhaul Indiana’s criminal code.

A clause in the article called for lowering marijuana possession charges, where Pence refused to accept the lowered penalties and demanded a bump back up to a Class B misdemeanor for cannabis possession. Indiana’s archaic drug laws haven’t been updated partly because of Pence’s belief that cannabis is a gateway drug.

 


Click Here To Read More



Medical Uses of Cannabis Throughout History

The discovery of cannabis’ medical properties can be traced back thousands of years, back to when its primary consumption was through eating the seeds for its high nutritional value. The seeds from inside the feminine flowers, their pollination referring to what we know as the buds. The buds hold the richest source of psychoactive and medically valuable cannabinoids.

About 2,800 B.C., a Chinese emperor who fathered a myriad of traditional Chinese medicines, praised cannabis as one its most valuable medicinal remedies. The flowers were used to overcome yin, rheumatism, malaria, constipation, memory loss, as well as menstrual cycle problems. In the second century, famous surgeon Hua To used a mixture of hemp resin and wine to compose anesthesia, performing complicated surgeries. References have been made to “kannabis” by the ancient Greeks. In 400 B.C., its use was documented for back pain, and in 70 A.C…

 


Read The Full Article Here


 

Subscribe Now & Begin Receiving Marijuana Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Marijuana Stocks, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on marijuana stocks related, articles, news and trade alerts. Further questions please contact privacy@marijuanastocks.com
Ad Placements